<DOC>
	<DOCNO>NCT00556374</DOCNO>
	<brief_summary>The purpose study determine whether denosumab compare placebo , reduce rate first clinical fracture woman non-metastatic breast cancer receiving ( non-steroidal ) aromatase inhibitor therapy . Subjects receive open-label denosumab followed-up completion 36 month treatment . Subject receive treatment open label phase follow approximately 66 month Primary analysis data cut-off date ( PADCD ) .</brief_summary>
	<brief_title>Study Determine Treatment Effects Denosumab Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Double Blinded Phase : Histologically cytologically confirm adenocarcinoma breast ; Female subject nonmetastatic disease estrogen receptor ( ER ) and/or progesterone receptor ( PR ) positive , complete treatment pathway ; Subjects currently , initiate approve nonsteroidal aromatase inhibitor therapy ( eg , anastrazole ) adjuvant setting ; Postmenopausal woman , define woman fulfil one follow criterion : Having undergone bilateral oophorectomy ; Age â‰¥ 60 year ; Aged &lt; 60 year meet following requirement : Folliclestimulating hormone ( FSH ) estradiol postmenopausal range ; A negative pregnancy test within 7 day prior randomization . Subjects undergone hysterectomy require pregnancy test . More criterion may apply . Exclusion Criteria Double Blinded Phase : Aromatase inhibitor therapy 24 month ; Prior concurrent treatment Selective Estrogen Receptor Modulators ( eg , tamoxifen ) ; Evidence metastatic disease ; Current prior intravenous ( IV ) bisphosphonate administration ; Oral bisphosphonate treatment great equal 3 year continuously OR great 3 month le 3 year unless washout period least 1 year prior randomization OR use 3month period prior randomization ; Prior administration denosumab ; Known liver renal deficiency ; Recurrence primary malignancy ( e.g. , allow interval pretreatment aromatase inhibitor ) ; Diagnosis second nonbreast malignancy within last 5 year , except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix uterus ; Any kind disorder compromise ability give write informed consent and/or comply study procedure . Inclusion Criteria Receive Openlabel Phase Denosumab : Obtain sign date write informed consent prior perform studyspecific procedure ; Subjects currently take approve nonsteroidal AIT ( eg , anastrazole ) complete discontinued AIT within 12 month prior participation OLP ; Randomized placebo arm doubleblind phase ( determine unblinding procedure ) ; Exclusion Criteria Receive Openlabel Phase Denosumab : Current prior IV bisphosphonate administration ; Subjects meeting follow criterion oral bisphosphonate treatment : Greater equal 3 year continuously , Greater 3 month le 3 year unless subject washout period least 1 year prior participation OLP , Any use 3month period prior participation OLP ; Prior concurrent treatment SERMs ( eg , tamoxifen ) ; Subjects end treatment investigational product ( IP ) prematurely doubleblind phase ; Treatment commercial denosumab ( Prolia Xgeva ) prior participation OLP .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>confirm adenocarcinoma</keyword>
	<keyword>non-metastatic breast cancer</keyword>
	<keyword>estrogen receptor positive</keyword>
	<keyword>progesterone receptor positive</keyword>
	<keyword>non-steroidal aromatase</keyword>
	<keyword>aromatase inhibitor therapy</keyword>
	<keyword>postmenopausal woman</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
</DOC>